北京招聘

职位描述：
Basic Summary:
This position is needed to help select/upgrade the database and software vendor(s) to meet the needs of compound management and data storage; design the data handling approach; data acquisition, analysis and reporting; set up and implement the software and associated hardware; test the data tracking and analysis functionality; oversee the smooth data flow and tracking during screening campaigns. This position will also help to expand compound library.

Essential Duties and Responsibilities:
? Proficiency with lab data software, including compound receipt and tracking, bioanalytical data storage and processing, and data reporting.
? Integrating automated processes such as barcoded plate and plate maps, generation of cherry-pick plates, integration with lab automation software, and data capture and reporting (for example, ActivityBase, Spotfire, or similar).
? Familiarity with LC/MS/MS bioanalysis, particularly with bioanalytical data handling and processing.
? Familiarity with high-throughput screening (HTS) data from enzyme-based or cell-based assays (including in vitro ADME assays) a plus.
? Knowledge on compound drug-like property, compound library construction, and combinatorial synthesis preferred.
? Excellent communication (written and oral) and collaborative skills.
? Proactive and self-driven attitude.
? Some degree of independence in planning and implementation of data generation and analysis tools.
? Effective trouble-shooting and problem solving skills.
? Ability to train and mentor staff.
? Perform all other duties as assigned
Qualifications
? Education: PH.D., M.S or equivalent in a scientific related discipline.
? Experience: Minimum of 5 years (senior director), 3 years (director), or 1 year (group leader) related experience in the contract research, academic, or pharmaceutical industry.
? An equivalent combination of education and experience may be accepted as a satisfactory substitute for the specific education and experience listed above. 举报 分享

百济神州是一家立足于科学的全球性生物科技公司，专注于开发创新、可负担的药物，旨在为全球患者改善治疗效果，提高药物可及性。目前公司广泛的药物组合包括40多款临床候选药物。公司通过加强自主研发能力和合作，加速推进多元、创新的药物管线开发。我们致力于在2030年前为全球20多亿人全面改善药物可及性。百济神州在全球五大洲打造了一支超过8,000人的团队。